ALK and lung carcinoma: For example, the first-generation ALK inhibitor crizotinib, as well as second- and third-generation drugs such as brigatinib, lorlatinib, alectinib, and ceritinib, have been included in guidelines for the treatment of lung cancer patients with ALK gene fusions (Wu et al., 2016).